Advertisement

GSK

GSK plc

Healthcare · USD

Set alert

Price alert · GSK

All alert types
49.51 USD +0.83 +1.71%
As of Oct 30, 2026 Extended hours 49.51 0.00%
Bid
49.48 × 500
Ask
49.55 × 200
49.25 Day range 50.28
46.11 52-week range 61.18
YTD
+0.96%
1 year
+5.48%
Open
49.84
Prev close
48.68
Mkt cap
99.19B
Vol
4.77M
Avg vol
4.07M
EPS
2.87
P/E
17.25
Div yield
3.73%
More statistics
Low
49.25
High
50.28
Forward P/E
9.99
Beta
0.28
Short ratio
2.86
Inst. own
17.46%
Dividend
1.82
Ex-div date
Aug 13, 2026
Earnings
Feb 3, 2027
50-d avg
49.48
200-d avg
52.35
1y target
60.40

5D chart

Chart tools
Interval
GSK five-day price chart47.448.349.350.351.3Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
99.12B
Enterprise value
118.03B
Trailing P/E
17.24
Forward P/E
9.99
PEG ratio
5.89
Price / sales
2.96
Price / book
3.95
EPS (TTM)
2.87
Beta
0.28
Dividend yield
3.73%
Payout ratio
63.33%
Profit margin
12.97%
Revenue (TTM)
33.54B
Revenue growth
4.00%
Free cash flow
5.33B
Total cash
2.96B
Total debt
23.80B
Return on equity
28.27%
Shares outstanding
2.00B
Short % of float
0.73%
50-day average
49.48
200-day average
52.35

Analyst view

Consensus: buy

Buy
Price target (mean) 60.40 +22.0% upside
Target (low)
49.00
Target (mean)
60.40
Target (high)
70.00
Ratings (0m) 9 4 buy · 4 hold · 1 sell
  • Strong buy1
  • Buy3
  • Hold4
  • Sell1
  • Strong sell0

Next earnings

Feb 3, 2027

Expected Feb 3, 2027. Consensus EPS estimate 0.74766.

Earnings history

Financials — quick view

All financials
GSK Revenue — quarterly 8.89B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
GSK Net income — quarterly 1.54B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
GSK EPS — quarterly 0.77
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

GSK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 3, 2027Dec 30, 20260.77———
Oct 28, 2026Sep 30, 20261.331.47+0.14+10.53%
Jul 28, 2026Jun 30, 20261.271.36+0.09+7.09%
Apr 29, 2026Mar 31, 20261.161.24+0.08+6.90%
Feb 4, 2026Dec 31, 20250.640.68+0.04+6.25%
Oct 29, 2025Sep 30, 20251.261.48+0.22+17.46%

Upgrades / downgrades

GSK analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026JefferiesdownBuyHold
Jan 6, 2026BarclaysdownEqual-WeightUnderweight
Nov 12, 2024JefferiesdownBuyHold
Oct 31, 2024GuggenheimdownBuyNeutral
Jul 8, 2024UBSdownBuyNeutral
Jul 2, 2024JefferiesmainBuyBuy

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United Kingdom
Website
gsk.com

News

Your note

Sign in to keep a note on GSK — it syncs with the Stock Master app.

Insider holders

GSK insider holders
InsiderRelationLatest transactionDateShares held
Anderson (Elizabeth McKee)—BoughtOct 8, 20264,938
Bancroft (Charles A)—BoughtOct 8, 202645,579
Barron (Hal V)—BoughtOct 8, 2026604,639
Beal (Anne M.D.)—BoughtOct 8, 20265,663
Conrad (D)—BoughtApr 26, 20267,571
Dietz (Hal)—BoughtOct 8, 20265,589

Institution ownership

GSK institution ownership
Holder% heldSharesValueReported
FMR, LLC3.21%64,961,6413.21BJun 29, 2026
Dodge & Cox Inc.2.38%48,197,5142.38BJun 29, 2026
Fisher Asset Management, LLC1.77%35,722,7921.77BJun 29, 2026
Primecap Management Company1.24%25,182,0681.25BJun 29, 2026
Wellington Management Group, LLP0.56%11,396,249563.83MJun 29, 2026
JTC Employer Solutions Trustee Ltd.0.42%8,592,987425.14MJun 29, 2026

Fund ownership

GSK fund ownership
Holder% heldSharesValueReported
Dodge & Cox Funds-Dodge & Cox Stock Fund1.76%35,573,7871.76BJun 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund0.90%18,172,650899.09MJun 29, 2026
VANGUARD WELLINGTON FUND0.47%9,498,942469.96MAug 30, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 0.40%8,018,227396.70MAug 30, 2026
Fidelity Hastings Street Trust-Fidelity Series Large Cap Stock Fund0.23%4,579,628226.58MAug 30, 2026
Fidelity Devonshire Trust-Fidelity Series Value Discovery Fund0.20%3,952,000195.53MAug 30, 2026
Advertisement